Concord Biotech Limited vs Onesource Specialty Pharma Limited
Last updated: 23 October 2026
Concord Biotech Limited vs Onesource Specialty Pharma Limited: A MoneyDock Comparison
In the dynamic Indian pharmaceutical sector, investors often seek opportunities in companies demonstrating growth potential and resilience. This comparison pits Concord Biotech Limited (CONCORDBIO.NS) against Onesource Specialty Pharma Limited (ONESOURCE.NS). While specific operational details of both companies are beyond the scope of this numerical comparison, both operate within the broader healthcare and pharmaceutical domain, making them relevant contenders for investors looking at this segment. Our analysis will strictly adhere to the provided financial metrics to offer an objective perspective on their current market standing.
Key Financial Metrics
| Metric | Concord Biotech Limited | Onesource Specialty Pharma Limited |
|---|---|---|
| Current Price | ₹1229.30 | ₹1334.10 |
| 52W High | ₹1579.40 | ₹1867.40 |
| 52W Low | ₹1014.80 | ₹1114.00 |
| 1-Year Return | -7.65% | -17.55% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Who Wins?
Based on the provided figures, a clear distinction can be drawn between these two pharmaceutical companies. When it comes to returns, Concord Biotech Limited significantly outperforms Onesource Specialty Pharma Limited. Concord has posted a 1-year return of -7.65%, which, while negative, is considerably better than Onesource's -17.55%. This suggests Concord has experienced less downward pressure or has shown greater resilience over the past year.
For stability and price range, Concord Biotech also appears to be in a slightly more favorable position. Its current price of ₹1229.30 is closer to its 52-week low of ₹1014.80 compared to its high of ₹1579.40. Onesource, with a current price of ₹1334.10, is also closer to its 52-week low of ₹1114.00 than its high of ₹1867.40. However, Concord's overall 52-week price range seems less volatile, with its high being approximately 1.5 times its low, whereas Onesource's high is roughly 1.67 times its low. This indicates potentially less severe price fluctuations for Concord within the last year.
Regarding valuation, both companies have a 'N/A' for Trailing P/E and Market Cap, which makes a direct comparison on traditional valuation metrics impossible with the given data. Investors would need to seek additional information on these fronts to make informed decisions about their intrinsic value.
Considering the metrics at hand, Concord Biotech Limited shows a stronger performance in terms of controlling losses over the last year and potentially exhibiting slightly less price volatility compared to Onesource Specialty Pharma Limited.
MoneyDock Verdict
For Aggressive Investors: Given the negative returns for both, aggressive investors might view the larger drop in Onesource (-17.55%) as a potentially bigger 'buy the dip' opportunity, assuming a strong belief in its future turnaround. However, the data alone doesn't support this with any fundamental valuation.
For Conservative Investors: Concord Biotech Limited, with its comparatively smaller 1-year loss (-7.65% vs -17.55%), appears to be the less risky option based purely on the provided historical price performance. It has demonstrated better capital preservation over the last year.
For Long-Term SIP Investors: Without P/E ratios or market caps, and both showing negative 1-year returns, it's difficult to recommend either for a long-term SIP based solely on this data. However, if forced to choose based on recent performance, Concord's relatively stronger return might make it marginally more appealing for consistent investment, hoping its resilience translates into future gains.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.